Braf inhibitors in thyroid cancer: Clinical impact, mechanisms of resistance and future perspectives

Fabiana Crispo, Tiziana Notarangelo, Michele Pietrafesa, Giacomo Lettini, Giovanni Storto, Alessandro Sgambato, Francesca Maddalena, Matteo Landriscina

Research output: Contribution to journalReview articlepeer-review


The Kirsten rat sarcoma viral oncogene homolog (RAS)/v-raf-1 murine leukemia viral oncogene homolog 1 (RAF)/mitogen-activated protein kinase 1 (MAPK) signaling cascade is the most important oncogenic pathway in human cancers. Tumors leading mutations in the gene encoding for v-raf murine sarcoma viral oncogene homolog B (BRAF) serine-threonine kinase are reliant on the MAPK signaling pathway for their growth and survival. Indeed, the constitutive activation of MAPK pathway results in continuous stimulation of cell proliferation, enhancement of the apoptotic threshold and induction of a migratory and metastatic phenotype. In a clinical perspective, this scenario opens to the possibility of targeting BRAF pathway for therapy. Thyroid carcinomas (TCs) bearing BRAF mutations represent approximately 29–83% of human thyroid malignancies and, differently from melanomas, are less sensitive to BRAF inhibitors and develop primary or acquired resistance due to mutational events or activation of alternative signaling pathways able to reactivate ERK signaling. In this review, we provide an overview on the current knowledge concerning the mechanisms leading to resistance to BRAF inhibitors in human thyroid carcinomas and discuss the potential therapeutic strategies, including combinations of BRAF inhibitors with other targeted agents, which might be employed to overcome drug resistance and potentiate the activity of single agent BRAF inhibitors.

Original languageEnglish
Article number1388
Issue number9
Publication statusPublished - Sep 2019


  • BRAF inhibitors
  • BRAF mutation
  • Mechanism of resistance
  • Thyroid cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Braf inhibitors in thyroid cancer: Clinical impact, mechanisms of resistance and future perspectives'. Together they form a unique fingerprint.

Cite this